Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Assembly BiosciencesASMB +2.54%34 Price-to-Tangible-Book is 2.23 as of Aug. 23, 2026, which is 9% below its 10-year median of 2.44. GuruFocus rates ASMB with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,128 Biotechnology companies, Assembly Biosciences ranks better than 65.25% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Assembly Biosciences Price-to-Tangible-Book Related Terms
Assembly Biosciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs ZURA, ARVN, ARTV: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Assembly Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Assembly Biosciences (ASMB) has a Price-to-Tangible-Book of 2.23 as of Aug. 23, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Assembly Biosciences and its competitors. This is near median its historical median of 2.44. Over the past decade, Assembly Biosciences' Price-to-Tangible-Book has ranged from 0.62 to 110.51. According to the industry distribution chart, Assembly Biosciences ranks #392 out of 1128 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Assembly Biosciences' Price-to-Tangible-Book too high?
Assembly Biosciences' current Price-to-Tangible-Book of 2.23 is near median its 10-year median of 2.44. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 110.51. The Biotechnology industry median Price-to-Tangible-Book is 3.28. Assembly Biosciences' value of 2.23 is 31.9% below this industry median. Based on the distribution chart, Assembly Biosciences ranks #392 out of 1128 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Price-to-Tangible-Book compare to ZURA and ARVN?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #392 out of 1128 companies for Price-to-Tangible-Book. This puts Assembly Biosciences in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.28. Assembly Biosciences' value of 2.23 is 31.9% below this benchmark. Historically, Assembly Biosciences' own Price-to-Tangible-Book has ranged from 0.62 to 110.51 over the past decade. While the company's 10-year median is 2.44 vs. the industry median of 3.28, Assembly Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.28, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Price-to-Tangible-Book of 2.23 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Price-to-Tangible-Book is 2.23, which is near median its own 10-year median of 2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Price-to-Tangible-Book of 2.23. The current Price-to-Tangible-Book is 2.23, which is near median its 10-year median of 2.44 and 31.9% below the Biotechnology industry median of 3.28. Assembly Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Price-to-Tangible-Book is 2.23 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
34GF Score
Get the complete analysis for ASMB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
